Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019, CA. Cancer J Clin 69:7–34. https://doi.org/10.3322/caac.21551

Article  Google Scholar 

Carioli M, Malvezzi T, Rodriguez P, Bertuccio E, Negri CL, Vecchia, (2018) Trends and predictions to 2020 in breast cancer mortality: Americas and Australasia. Breast 37:163–169. https://doi.org/10.1016/j.breast.2017.12.004

Article  PubMed  Google Scholar 

Iacoviello L, Bonaccio M, De Gaetano G, Benedetta M (2021) Seminars in Cancer Biology Epidemiology of breast cancer, a paradigm of the “common soil” hypothesis. Semin Cancer Biol 72:4–10. https://doi.org/10.1016/j.semcancer.2020.02.010

Article  CAS  PubMed  Google Scholar 

Derks MGM, Bastiaannet E, van de Water W, de Glas NA, Seynaeve C, Putter H, Nortier JWR, Rea D, Hasenburg A, Markopoulos C, Dirix LY, Portielje JEA, van de Velde CJH, Liefers GJ (2018) Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial. Eur J Cancer 99:1–8. https://doi.org/10.1016/j.ejca.2018.04.009

Article  CAS  PubMed  Google Scholar 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(2018):394–424. https://doi.org/10.3322/caac.21492

Article  PubMed  Google Scholar 

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge Ø, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale A-L, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752. https://doi.org/10.1038/35021093

Article  CAS  PubMed  Google Scholar 

Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7:4–13. https://doi.org/10.3121/cmr.2009.825

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:1–10. https://doi.org/10.1186/bcr1639

Article  CAS  Google Scholar 

Giuliano M, Trivedi MV, Schiff R (2013) Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications. Breast Care (Basel) 8:256–262. https://doi.org/10.1159/000354253

Article  Google Scholar 

Iancu G, Vasile D, Iancu RC, DaviŢoiu DV (2017) “Triple positive” breast cancer—a novel category? Rom J Morphol Embryol Rev Roum Morphol Embryol 58:21–26

Google Scholar 

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (80-) 235:182–191. https://doi.org/10.1126/science.3798106

Article  Google Scholar 

Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76:27–36. https://doi.org/10.1023/a:1020299707510

Article  CAS  PubMed  Google Scholar 

Cui X, Schiff R, Arpino G, Osborne CK, Lee AV (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol Off J Am Soc Clin Oncol 23:7721–7735. https://doi.org/10.1200/JCO.2005.09.004

Article  CAS  Google Scholar 

Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol Off J Am Soc Clin Oncol 26:1059–1065. https://doi.org/10.1200/JCO.2007.12.9437

Article  CAS  Google Scholar 

De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D’Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S (2005) A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11:4741–4748. https://doi.org/10.1158/1078-0432.CCR-04-2569

Article  PubMed  Google Scholar 

Brandão M, Caparica R, Malorni L, Prat A, Carey LA, Piccart M (2020) What Is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer? Clin Cancer Res 26:2783–2788. https://doi.org/10.1158/1078-0432.CCR-19-2612

Article  PubMed  PubMed Central  Google Scholar 

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE, Pazdur R, Ditsch N, Rastogi P, Eiermann W, Von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172. https://doi.org/10.1016/S0140-6736(13)62422-8

Article  PubMed  Google Scholar 

Dieci MV, Guarneri V, Vittoria M, Guarneri V (2020) Expert Review of Anticancer Therapy Should triple-positive breast cancer be recognized as a distinct subtype ? Expert Rev Anticancer Ther 20:1011–1014. https://doi.org/10.1080/14737140.2020.1829484

Article  CAS  PubMed  Google Scholar 

Marchiò C, Natrajan R, Shiu KK, Lambros MBK, Rodriguez-Pinilla SM, Tan DSP, Lord CJ, Hungermann D, Fenwick K, Tamber N, Mackay A, Palacios J, Sapino A, Buerger H, Ashworth A, Reis-Filho JS (2008) The genomic profile of HER2-amplified breast cancers: the influence of ER status. J Pathol 216:399–407. https://doi.org/10.1002/path.2423

Article  PubMed  Google Scholar 

Montemurro F, Rossi V, Cossu Rocca M, Martinello R, Verri E, Redana S, Adamoli L, Valabrega G, Sapino A, Aglietta M, Viale G, Goldhirsch A, Nolè F (2012) Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer 118:17–26. https://doi.org/10.1002/cncr.26162

Article  CAS  PubMed  Google Scholar 

Bhargava R, Dabbs DJ, Beriwal S, Yildiz IA, Badve P, Soran A, Johnson RR, Brufsky AM, Lembersky BC, McGuire KP, Ahrendt GM (2011) Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. Mod Pathol 24:367–374. https://doi.org/10.1038/modpathol.2010.209

Article  CAS  PubMed  Google Scholar 

Ropero S, Menéndez JA, Vázquez-Martín A, Montero S, Cortés-Funes H, Colomer R (2004) Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat 86:125–137. https://doi.org/10.1023/b:brea.0000032981.20384.c6

Article  CAS  PubMed  Google Scholar 

Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825–2831

CAS  PubMed  Google Scholar 

Yu F-L, Bender W (2002) A proposed mechanism of tamoxifen in breast cancer prevention. Cancer Detect Prev 26:370–375. https://doi.org/10.1016/s0361-090x(02)00124-1

Article  CAS  PubMed  Google Scholar 

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013

Article  CAS  PubMed  Google Scholar 

Kowalczyk T, Ciborowski M, Kisluk J, Kretowski A, Barbas C (2020) Mass spectrometry based proteomics and metabolomics in personalized oncology. BBA Mol Basis Dis 1866:165690. https://doi.org/10.1016/j.bbadis.2020.165690

Article  CAS  Google Scholar 

Parker CE, Borchers CH (2014) Mass spectrometry based biomarker discovery, verification, and validation—quality assurance and control of protein biomarker assays. Mol Oncol 8:840–858. https://doi.org/10.1016/j.molonc.2014.03.006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Srivastava A, Creek DJ (2019) Discovery and validation of clinical biomarkers of cancer: a review combining metabolomics and proteomics. Proteomics 19:e1700448. https://doi.org/10.1002/pmic.201700448

Article  CAS  PubMed  Google Scholar 

Nice EC (2016) From proteomics to personalized medicine: the road ahead. Expert Rev Proteom 13:341–343. https://doi.org/10.1586/14789450.2016.1158107

Article  CAS  Google Scholar 

Pralea I, Moldovan R, Ionescu C, Iuga C (2020) Mass spectrometry-based omics for the characterization of triple-negative breast cancer bio-signature. J Pers Med 10:1–16

Article  Google Scholar 

Chen G, Pramanik BN (2009) Application of LC/MS to proteomics studies: current status and future prospects. Drug Discov Today 14:465–471. https://doi.org/10.1016/j.drudis.2009.02.007

Article  CAS  PubMed  Google Scholar 

Chen G, Pramanik BN, Liu Y-H, Mirza UA (2007) Applications of LC/MS in structure identifications of small molecules and proteins in drug discovery. J Mass Spectrom 42:279–287. https://doi.org/10.1002/jms.1184

Article  CAS  PubMed  Google Scholar 

Bertucci F, Birnbaum D, Goncalves A (2006) Proteomics of breast cancer: principles and potential clinical applications. Mol Cell Proteom 5:1772–1786. https://doi.org/10.1074/mcp.R600011-MCP200

Article  CAS  Google Scholar 

Gonc A, Toiron Y, Esterni B, Monville F, Tarpin C, Jacquemier J, Houvenaeghel G, Chabannon C, Extra J, Viens P, Borg J, Birnbaum D (2008) Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes * □. Mol Cell Proteom 7:1420–1433. https://doi.org/10.1074/mcp.M700487-MCP200

Article  CAS  Google Scholar 

Semreen M, Alniss H, Al-Awady R, Mousa M, Almehdi A, Soares N (2020) GC-MS based comparative metabolomic analysis of MCF7 and MDA-MB-231 cancer cells treated with Tamoxifen and/or Taxol. FASEB J 34:1

Article  Google Scholar 

Semreen MH, Alniss H, Cacciatore S, El-Awady R, Mousa M, Almehdi AM, El-Huneidi W, Zerbini L, Soares NC (2020) GC-MS based comparative metabolomic analysis of MCF-7 and MDA-MB-231 cancer cells treated with Tamoxifen and/or Paclitaxel. J Proteom 225:103875. https://doi.org/10.1016/j.jprot.2020.103875